The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial infarction (AMI) does not decrease regardless of implementation of new technologies supporting opening culprit coronary artery and solving of ischemia-relating stenosis with primary percutaneous coronary intervention (PCI). Numerous studies have examined the diagnostic and prognostic potencies of circulating cardiac biomarkers in acute coronary syndrome/AMI and heart failure after AMI, and even fewer have depicted the utility of biomarkers in AMI patients undergoing primary PCI. Although complete revascularization at early period of acute coronary syndrome/AMI is an established factor for improved short-term and long-term prognosis and lowered risk of cardiovascular (CV) complications, late adverse cardiac remodelling may be a major risk factor for one-year mortality and postponded heart failure manifestation after PCI with subsequent blood flow resolving in culprit coronary artery. The aim of the review was to focus an attention on circulating biomarker as a promising tool to stratify AMI patients at high risk of poor cardiac recovery and developing HF after successful PCI. The main consideration affects biomarkers of inflammation, biomechanical myocardial stress, cardiac injury and necrosis, fibrosis, endothelial dysfunction, and vascular reparation. Clinical utilities and predictive modalities of natriuretic peptides, cardiac troponins, galectin 3, soluble suppressor tumorogenicity-2, high-sensitive C-reactive protein, growth differential factor-15, midregional proadrenomedullin, noncoding RNAs, and other biomarkers for adverse cardiac remodelling are discussed in the review.

中文翻译：

---

急性心肌梗死后不良心脏重塑：新旧生物标志物。

不管采用新技术来支持开颅罪犯冠状动脉和通过原发性经皮冠状动脉介入治疗（PCI）解决与缺血相关的狭窄，无论急性心肌梗死（AMI）后由于心脏重塑导致的心力衰竭（HF）患病率均不会降低。许多研究已经检查了循环心脏生物标志物在急性冠脉综合征/ AMI和AMI后心力衰竭中的诊断和预后效力，甚至更少的研究表明生物标志物在接受原发性PCI的AMI患者中的作用。尽管急性冠脉综合征/ AMI早期完全血运重建是改善短期和长期预后并降低心血管（CV）并发症风险的确定因素，晚期不良心脏重塑可能是一年后死亡率和PCI后心衰推迟的主要危险因素，随后在罪犯冠状动脉中出现血流溶解。综述的目的是将注意力集中在循环生物标志物上，将其作为成功的PCI后将有心脏复苏不良和心力衰竭高风险高风险的AMI患者分层的有前途的工具。主要考虑因素影响炎症，生物力学心肌应激，心脏损伤和坏死，纤维化，内皮功能障碍和血管修复的生物标志物。利钠肽，心脏肌钙蛋白，半乳糖凝集素3，可溶性抑制物致瘤性2，高敏感性C反应蛋白，生长分化因子15，中部肾上腺髓质素，非编码RNA，的临床用途和预测方式